De-risked cell therapies for the world's most complex diseases.
Static "omics" snapshots tell you what a cell contains, not what it's doing. We read the living network of protein interactions: the layer where a cell's behavior is actually decided. Then AI/ML finds the patterns that predict outcomes.
Hundreds of intracellular interactions, at once.
AI/ML learns the hidden patterns.
Signals become predictive biosignatures.
Insights inform the engineering of cures.
Our QMI platform is a functional assay: it captures hundreds of protein interactions straight from a single, unmodified sample of living cells.
QMI runs on a tiny amount of living cells, even leftover clinical product. No genetic tags, no engineering.
It captures the signaling complexes intact, just as they formed inside the cell. Measured, not modeled.
A single run quantifies hundreds of protein-protein interactions in parallel, not one pair at a time.
Each run turns the living network into hundreds of quantitative data points: the signal that trains our AI/ML to predict clinical outcomes.
Our latest paper shows that QMI biosignatures from CAR-T products correlate with patient outcomes.
CD28 signaling complexes are correlated with patient outcomes in anti-CD19 4-1BB-costimulation CAR T cell therapy Read the paper ↗We're building the predictive layer for cell therapy. If you're an investor, a strategic, or a research partner, reach out.
[ Contact Us ]